|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 905 16th ST NW |
Address2 | Suite 400 |
| City | Washington |
State | DC |
Zip Code | 20006 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | Schaumburg |
State | IL |
Zip Code | 60173-4973 |
Country | USA |
|
5. Senate ID# 3388-12
|
||||||||
|
6. House ID# 315460000
|
||||||||
| TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Manuel Bonilla |
Date | 1/19/2021 11:02:57 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare Access and CHIP Reauthorization Act (PL 114-10)
S.2157, Rural Hospital Sustainability Act: CMMI payment model to rural hospitals
H.R.1763, Resident Physician Shortage Reduction Act of 2019:residency positions eligible for graduate medical education payments
H.R. 1384, Medicare for All Act of 2019: Medicare for All
H.R. 4056, Medicare Audiologist Access and Services Act of 2019: audiology
H.R. 5774, Combating Opioid Abuse for Care in Hospitals Act of 2018: Opioids
H.R. 6, SUPPORT for Patients and Communities Act: Opioids
H.R. 2550, Medicare Telehealth Parity Act of 2017
H.R. 676, Expanded and Improved Medicare for All Act: Medicare for All, payment
H.R. 8702, Holding Providers Harmless From Medicare Cuts During COVID-19 Act of 2020: payment
H.R. 8756, COVID Health Care Provider Assurance Act of 2020: payment
Independent Payment Advisory Board (IPAB) Repeal
Rural Anesthesiology: Rural Pass Through
Out of Network/Out of Network Payment
Historical Medicare payment undervaluation for anesthesiology services (33% problem)
Anesthesia Conversion Factor
Perioperative Surgical Home Model
Bundled payments
CMS 45 CFR Parts 147, 155, and 156, PPACA; Market Stabilization rule
CMS Interpretive Guidelines: Hospital Conditions of Participation Related to Anesthesia Services
2017 Medicare Physician Fee Schedule Rule
CMS decision to decrease values of interlaminar epidural injections
CMS Value-Based purchasing
CMS Medicare Data Final Rule
Sunshine Act Implementation
Conditions of Participation - Anesthesia services, opt-outs, supervision
Physician Quality Reporting System, PPACA, Sec. 3007 Quality Modifier implementation
IPAB cuts
Graduate Medical Education
Value-based modifier - PPACA
Debt ceiling - Medicare sequestration
QCDR - Qualified Clinical Data Registry
CMS Meaningful Use Stage 3
Executive Order Promoting Healthcare Choice and Competition (Trumpcare)
Ambulatory Surgery Center
Critical Care and Anesthesia Services Payment Reform: Increase payments for anesthesia and critical care services for Medicare COVID patients
Prescription Drug Management Programs: Evaluation and Monitoring codes & cuts
Certified Anesthesiologist Assistants
Public Option
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Government Accountability Office (GAO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Manuel |
Bonilla |
|
|
|
Sharon |
Merrick |
|
|
|
Nora |
Matus |
|
|
|
Matthew |
Popovich |
|
|
|
Ashley |
Walton |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
S.3548, CARES Act: To provide emergency assistance and health care response for individuals, families, and businesses affected by the 2020 coronavirus pandemic; Practice Support/Grants to Practice
S.3599, Healthcare Workforce Resilience Act: Foreign physician immigration status
H.R. 7059, Coronavirus Provider Protection Act: Liability protection for healthcare providers
Public Law No: 116-142, Paycheck Protection Program Flexibility Act of 2020
S.3201, Temporary Reauthorization and Study of the Emergency Scheduling of Fentanyl Analogues Act: Letter to Congressional Leadership regarding Fentanyl
S.2723, Mitigating Emergency Drug Shortages Act: reducing drug shortages
H.R. 3502, Protecting People From Surprise Medical Bills Act: Surprise Medical Bills
H.R. 2500, National Defense Authorization Act for Fiscal Year 2020: Krishnamoorthi amdt on drug shortages
H.R. 3107, Improving Seniors' Timely Access to Care Act of 2019: pre-authorization
S. 1895, Lower Health Care Costs Act
H.R. 3692, Addiction Treatment Access Improvement Act of 2017: Medically assisted treatment; opioids
H.R. 5761, Ending Maternal Mortality Act of 2018: Maternal mortality
H.R. 5718, Perioperative Reduction of Opioids Act: Opioids
H.R. 5197, Alternatives to Opioids (ALTO) in the Emergency Department Act: Medically assisted treatment; opioids
S. 2516, Alternatives to Opioids (ALTO) in the Emergency Department Act: Medically assisted treatment; opioids
S.2680, Opioid Crisis Response Act of 2018: Medically assisted treatment; opioids
S.2456, CARA 2.0 Act of 2018: Medically assisted treatment; opioids
H.R. 1565, Saving Lives, Saving Costs
S.1475, Saving Lives, Saving Costs
S.4349, Dr. Lorna Breen Health Care Provider Protection Act: physician health
Comprehensive Addiction and Recovery Act of 2016 (PL 114-198)
FY 2021 LHHS Appropriations: Fiscal Year 2021 Appropriations for Subcommittee on Labor, Health and Human Services Outside Witness Testimony
Affordable Care Act reform efforts
H.R. 1628, American Health Care Act of 2017
S. Amdt. 1030 to H.R. 1628, "Graham-Cassidy"
Better Care Reconciliation Act of 2017
H.R. 1492, Medical Controlled Substances Transportation Act of 2017
H.R. 1215, Protecting Access to Care Act of 2017
H.R. 3545, Overdose Prevention and Patient Safety Act
H.R. 3446, Restoring Board Immunity Act of 2017: Professional Licensing
S.2260, Opioids and STOP Pain Initiative ACT:opioids
42 CFR Part 2, Confidentiality of Substance Use Disorder Patient Records: appropriate access to patient information essential for providing whole-person care
H.R.3928, Truth in Healthcare Marketing Act of 2017
H.R. 1554, REDI Act: student loan debt repayment for residents
21st Century Cures Initiative
Drug Shortages - FDA, DEA, HHS, CMS, GAO, House Energy and Commerce Committee, Senate HELP Committee
DEA Scheduling Propofol
Comparative Effectiveness Research - PCORI
HITECH Implementation, Electronic Health Records, Final and Proposed Rules, HIT Meaningful Use
HHS/OIG Anesthesia Practice Arrangements, Company Model
FDA Safe Use Initiative
Pain Management
FTC Letters to States re: Interventional Pain Medicine & Advanced Practice Nurses & Competition in Healthcare
Anesthesia Research Funding (Pediatric and others)
Scope of Practice
FDA Operating Room Fires
Naloxone
FDA Opioids
Prescription Drug Abuse
FDA Network of Experts
NIH Interagency Pain Research Coordinating Committee
FDA SMART TOTS - pediatric anesthesia research
USP - US Pharmacopeia
National Pain Strategy
Nondiscrimination
Compounding
FDA Nominations to Advisory Committees (Anesthesia Drugs, Anesthesia Devices, Compounding)
Agency for Healthcare Research and Quality (AHRQ) funding
Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS)
Sequestration
Opioids and opioid abuse; Brain health
Certified Anesthesiologist Assistants
Blood management
COVID-19: Increased supply of PPE and ventilators, Funding for physician practices impacted by the cancellation of elective surgeries, unique role of anesthesiologists in responding to COVID-19 pandemic, medical liability, Scope of Practice (Waiver of federal supervision requirement under the Emergency Declaration), insurance moratorium; COVID Update Memorandum 4/21/20
Centre for Clinical and Applied Services Provision Research
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Justice - Dept of (DOJ), Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Office of Management & Budget (OMB), Executive Office of the President (EOP), Defense - Dept of (DOD), Occupational Safety & Health Administration (OSHA), Federal Trade Commission (FTC), Veterans Affairs - Dept of (VA), Natl Institutes of Health (NIH), Centers For Medicare and Medicaid Services (CMS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Manuel |
Bonilla |
|
|
|
Sharon |
Merrick |
|
|
|
Nora |
Matus |
|
|
|
Matthew |
Popovich |
|
|
|
Ashley |
Walton |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Veterans Affairs Advance Practice Registered Nurses - "VHA Nursing Handbook"
Milcon VA Annual Appropriations
H.R.1783, Improving Veterans Access to Quality Care Act of 2017
VA Physician/Provider Hiring
VA Stone Memorandum, April 21, 2020: physician supervision
17. House(s) of Congress and Federal agencies Check if None
Veterans Affairs - Dept of (VA), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Manuel |
Bonilla |
|
|
|
Sharon |
Merrick |
|
|
|
Nora |
Matus |
|
|
|
Matthew |
Popovich |
|
|
|
Ashley |
Walton |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |